transmembrane protein 81Genealiases: HC3107 · KVLA2788 · UNQ2788
Q-omics provides the consensus-scored TMEM81 profile across patient tissues and cancer cell-line models. TMEM81 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TMEM81 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, TMEM81 RNA expression shows 18,315 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, HNSC, and ACC as cancer lineages where TMEM81 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM81 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM81 survival associations across molecular data types. TMEM81 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM81 RNA expression–survival associations across cancer types. High TMEM81 expression shows unfavorable associations in KIRC, ACC, UVM, LIHC, COAD and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TMEM81 RNA expression.
This table summarizes TMEM81 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM81. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM81 shows higher tumor expression in HNSC, LIHC, LUAD, STAD, COAD and LUSC. The HNSC box plot shows higher TMEM81 RNA expression in tumor versus normal tissue (log2 FC = +0.931, t-test p < 0.001).
This table shows molecular features associated with TMEM81 in patient tissues and cancer cell lines. In patient samples, TMEM81 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM81 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and LARGE_INTESTINE.
